参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Gastric Cancer Version 1.2019 — March 14, 2019.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).
3.World Health Organization.International Agency for Research on Cancer.GLOBOCAN 2018: stomach cancer fact sheet.2018.
4.Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018.CA Cancer J Clin 2018, 68: 7-30.
5.Lim YC, di Pietro M, O’Donovan M, et al.Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance.Gastrointest Endosc 2014, 80: 78-87.
6.Carvajal-Carmona LG.PALB2 as a familial gastric cancer gene: is the wait over? Lancet Gastroenterol Hepatol 2018.
7.Fewings E, Larionov A, Redman J, et al.Germline pathogenic variants in PALB2 and other cancerpredisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.Lancet Gastroenterol Hepatol 2018, 3: 489-498.
8.De Andrade JP, Mezhir JJ.The critical role of peritoneal cytology in the staging of gastric cancer: an evidencebased review.J Surg Oncol 2014, 110: 291-297.
9.Smyth EC, Fassan M, Cunningham D, et al.Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial.J Clin Oncol 2016, 34: 2721-2727.
10.Van Cutsem E, Bang YJ, Feng-Yi F, et al.HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.Gastric Cancer 2015, 18: 476-484.
11.U.S.Food and Drug Administration.FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication.2017.(https://www.daowen.com)
12.Cho J, Lee J, Bang H, et al.Programmed cell death-ligand1expression predicts survival in patients with gastric carcinoma with microsatellite instability.Oncotarget 2017, 8: 13320-13328.
13.Sohn BH, Hwang JE, Jang HJ, et al.Clinical significance of four molecular subtypes of gastric cancer identified by the Cancer Genome Atlas project.Clin Cancer Res 2017.
14.El-Sedfy A, Dixon M, Seevaratnam R, et al.Personalized surgery for gastric adenocarcinoma: a meta-analysis of D1 versus D2 lymphadenectomy.Ann Surg Oncol 2015, 22: 1820-1827.
15.Liu GF, Bair RJ, Bair E, et al.Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy.PLoS One 2014, 9: e82642.
16.Al-Batran SE, Lorenzen S.Management of locally advanced gastroesophageal cancer: still a multidisciplinary global challenge? Hematol Oncol Clin North Am 2017, 31: 441-452.
17.Shapiro J, van Lanschot JJB, Hulshof M, et al.Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS): long-term results of a randomised controlled trial.Lancet Oncol 2015, 16: 1090-1098.
18.Cats A, Jansen EPM, van Grieken NCT, et al.Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer(CRITICS): an international, open-label, randomised phase 3 trial.Lancet Oncol 2018.
19.Satoh T, Lee KH, Rha SY, et al.Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.Gastric Cancer 2015, 18: 824-832.
20.Janjigian YY, Ott PA, Calvo E, et al.Nivolumab ±ipilimumab in pts with advanced(adv)/metastatic chemotherapy-refractory(CTx-R)gastric(G), esophageal(E), or gastroesophageal junction(GEJ)cancer: CheckMate 032 study.J Clin Oncol 2017, 35: 4014.
21.Fuchs CS, Doi T, Jang RW, et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial.JAMA Oncol 2018, 4: e180013.
22.Reynolds J, Chamberland-Tremblay A, Herrington JD, et al.Highversus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer.J Oncol Pharm Pract 2017, 23: 173-178.